Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Sanofi raises profit forecasts after strong second quarter

Published 29/07/2021, 06:49
Updated 29/07/2021, 06:50
© Reuters. FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020.  REUTERS/Charles Platiau/File Photo

© Reuters. FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. REUTERS/Charles Platiau/File Photo

© Reuters. FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020.  REUTERS/Charles Platiau/File Photo

PARIS (Reuters) - Sanofi (PA:SASY) raised its 2021 outlook after its vaccines and star eczema treatment Dupixent helped it post better-than-expected second-quarter results on Thursday.

The French drugmaker said it was now targeting earnings per share to grow around 12% at constant exchange rates this year. It had previously been expecting a "high single digit" rise in earnings.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.